Acumen Pharmaceuticals (ABOS) Current Assets (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Current Assets of $133.1 million for Q1 2026, up 8.87% sequentially from $122.3 million in Q4 2025, and down 14.1% YoY from $154.9 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Current Assets (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Current Assets for 7 years, with the latest figure at $133.1 million in Q1 2026.
- Quarterly Current Assets fell 14.1% year-over-year to $133.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.1 million (down 14.1% YoY) and the FY2025 annual result came in at $122.3 million, down 31.44% from the prior year.
- Current Assets climbed to $133.1 million in Q1 2026 per ABOS's latest filing, from $122.3 million in the prior quarter.
- Over five years, Current Assets peaked at $266.9 million in Q2 2024 and troughed at $122.3 million in Q4 2025.
- A 5-year average of $183.8 million and a median of $180.3 million in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2025: Current Assets soared 170.72% in 2022, then slumped 44.4% in 2025.
- Over 5 years, Current Assets stood at $180.3 million in 2022, then surged by 36.76% to $246.6 million in 2023, then slipped by 27.7% to $178.3 million in 2024, then sank by 31.44% to $122.3 million in 2025, then gained by 8.87% to $133.1 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $133.1 million, $122.3 million, and $132.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 115.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.51 Mn |
| Mar 31, 2026 | 133.09 Mn |
| Dec 31, 2025 | 122.25 Mn |
| Sep 30, 2025 | 132.15 Mn |
| Jun 30, 2025 | 148.40 Mn |
| Mar 31, 2025 | 154.95 Mn |
| Dec 31, 2024 | 178.31 Mn |
| Sep 30, 2024 | 207.63 Mn |
| Jun 30, 2024 | 266.92 Mn |
| Mar 31, 2024 | 255.83 Mn |
| Dec 31, 2023 | 246.62 Mn |
| Sep 30, 2023 | 218.60 Mn |
| Jun 30, 2023 | 149.54 Mn |
| Mar 31, 2023 | 144.03 Mn |
| Dec 31, 2022 | 180.33 Mn |
| Sep 30, 2022 | 202.56 Mn |
| Jun 30, 2022 | 191.05 Mn |
| Mar 31, 2022 | 192.10 Mn |
| Dec 31, 2021 | 198.66 Mn |
| Sep 30, 2021 | 204.91 Mn |